

# SkinBioTherapeutics PLC

08:02 13 Jan 2021

## SkinBioTherapeutics says AxisBiotix subsidiary has commenced enrolment for its food supplement consumer study

SkinBioTherapeutics PLC (LON:SBTX), a life science company focused on skin health, announced that AxisBiotix Limited, a wholly-owned subsidiary of the company, has commenced enrolment for its food supplement consumer study.

Further to research exploring the relationship between the gut and the skin and the scientific evidence pointing to a link between gut dysfunction, stress-induced alterations to the gut microbiome and skin inflammation, the company noted that it has been working with Winclove Probiotics B.V. for the development of a blend of bacterial strains as a food supplement.

A proprietary blend of bacterial strains has been specifically designed to balance the gut microbiome to address the overproduction of new skin cells often seen in aggressive skin conditions such as psoriasis. Psoriasis is a debilitating skin condition caused by a malfunction of the immune system whereby raised 'plaques' form on the skin, which can be flaky, scaly and itchy.

### READ: SkinBioTherapeutics preparing to kick off psoriasis study as it eyes a busy year

There is currently no cure for psoriasis; therapies tend to be steroid-based, which cannot be used long term and have side effects. The condition is common, with approximately 2% of the global population believed to suffer from psoriasis.

With Winclove having completed formulation and manufacture of the supplement, and unable to initiate its clinic-based human study due to the coronavirus (COVID-19) restrictions, SkinBioTherapeutics has established a protocol for a 'self-managed' food supplement study.

The study, which will accept approximately 200 applicants, is now open for enrolment through the website [www.axisbiotix.com](http://www.axisbiotix.com). The participants will be asked to take a powdered food supplement dissolved in a glass of water on a daily basis and the study will run for a total of 56 days (2 x 28-day blocks).

Thereafter the data will be collated and analysed to assess the impact the supplement has had on the health of the skin. The study is monitored through a mobile phone application with frequent questions for participants and the submission of photographs of affected areas taken using their smart devices. As such the study is not impacted by current COVID-19 restrictions.

The supplements have been manufactured by Winclove and are currently being packaged ahead of shipment to the company in early February. The supplements will then be dispatched to the study participants with an expected start date before the end of February 2021.

**Price:** 38.475

**Market Cap:** £59.98 m

#### 1 Year Share Price Graph



March 2020 August 2020 February 2021

#### Share Information

**Code:** SBTX

**Listing:** AIM

52 week	High	Low
	44.5	4.98677

**Sector:** Pharma & Biotech

**Website:** [www.skinbiotherapeutics.com](http://www.skinbiotherapeutics.com)

#### Company Synopsis:

*SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by CEO Dr. Catherine O'Neill and Professor Andrew McBain at The University of Manchester. The SkinBioTherapeutics' platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to skin.*

[action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

The study will conclude before the end of April 2021 and the company expects to be able to report on the study findings shortly thereafter. Subject to a positive outcome, the company will then target a commercial launch of the product during the course of 2021 and in parallel initiate a clinic-based study looking at specific markers.

In a statement, Stuart Ashman, CEO of SkinBioTherapeutics, commented: "2020 was a year of transition for SkinBioTherapeutics with a focus on flexibility. We managed a smooth evolution from research into development, and proactively managed our way around the ever-changing obstacles that the global pandemic presented and continues to present.

"The preparatory work carried out last year has ensured that we remain on track with all our strategic and commercial goals as we move into 2021, where we expect to see significant progress across several of our strategic channels. The launch of the AxisBiotix website and the recruitment of candidates for our AxisBiotix-PS study, as well as the ongoing progress made by Sederma with our skincare programme, heralds the start of our commercialisation drive."

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of SkinBioTherapeutics PLC named herein, including the promotion by the Company of SkinBioTherapeutics PLC in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).